Read by QxMD icon Read

Journal of Clinical Lipidology

Hayato Tada, Masa-Aki Kawashiri, Akihiro Nomura, Ryota Teramoto, Kazuyoshi Hosomichi, Atsushi Nohara, Akihiro Inazu, Hiroshi Mabuchi, Atsushi Tajima, Masakazu Yamagishi
BACKGROUND: The genetic background of severe familial hypercholesterolemia (FH) has yet to be determined. OBJECTIVE: We tested if genetic variants associated with low-density lipoprotein (LDL)-altering autosomal recessive diseases influenced LDL cholesterol levels and the odds for coronary artery disease in patients with high LDL cholesterol. METHODS: We recruited 500 individuals with elevated LDL cholesterol levels (≥180 mg/dL or ≥140 mg/dL for subjects <15 years)...
August 23, 2018: Journal of Clinical Lipidology
Matthias P Nägele, Jens Barthelmes, Valeria Ludovici, Silviya Cantatore, Michelle Frank, Frank Ruschitzka, Andreas J Flammer, Isabella Sudano
BACKGROUND: Hypercholesterolemia is one of the most important contributors to atherosclerosis. Whether hypercholesterolemia also affects the retinal microcirculation is unclear. OBJECTIVE: The goal of our study was to assess the association of cholesterol levels with retinal microvascular function using dynamic and static retinal vessel analysis (RVA) in a primary prevention setting. METHODS: This cross-sectional, observational study prospectively recruited 67 patients with hypercholesterolemia without known cardiovascular disease (mean age 64...
August 18, 2018: Journal of Clinical Lipidology
Katherine S Rhodes, Carol F Kirkpatrick
No abstract text is available yet for this article.
August 18, 2018: Journal of Clinical Lipidology
Brian T Steffen, Daniel Duprez, Moyses Szklo, Weihua Guan, Michael Y Tsai
BACKGROUND: Limited evidence has suggested that circulating levels of the omega-9 fatty acid, oleic acid, may be related to greater risks of adverse cardiovascular outcomes. OBJECTIVE: We aimed to determine whether plasma oleic acid may be independently associated with clinical and subclinical cardiovascular disease (CVD) and all-cause mortality in a large multiethnic cohort. METHODS: Plasma fatty acids were measured by gas chromatography-flame ionization in 6568 participants of the Multi-Ethnic Study of Atherosclerosis...
August 16, 2018: Journal of Clinical Lipidology
Felipe Vendrame, Leticia Olops, Sara Teresinha Olalla Saad, Fernando Ferreira Costa, Kleber Yotsumoto Fertrin
BACKGROUND: High blood cholesterol is associated with atherogenesis and endothelial dysfunction. The latter is present in hemolytic diseases, such as sickle cell anemia, whose carriers have hypocholesterolemia and low incidence of coronary artery disease. OBJECTIVE: We aimed to characterize cholesterol fractions in patients with sickle cell disease and explore the relationship among lipoproteins, varying degrees of hemolysis, and its biomarkers. METHODS: We recruited 37 healthy individuals, 39 with hemoglobin SC disease, and 40 with sickle cell anemia and quantified cholesterol fractions, heme resulting from hemoglobin breakdown, and its main scavenger protein hemopexin...
August 14, 2018: Journal of Clinical Lipidology
Jan Oscarsson, Kristina Önnerhag, Ulf Risérus, Mattias Sundén, Lars Johansson, Per-Anders Jansson, Linda Moris, Peter M Nilsson, Jan W Eriksson, Lars Lind
BACKGROUND: Treatment with omega-3 fatty acids and fenofibrates reduces serum triglyceride levels, but few studies have compared the effect of these agents on liver fat. OBJECTIVE: The aim of the EFFECT I trial (NCT02354976) was to determine the effects of free omega-3 carboxylic acids (OM-3CA) and fenofibrate on liver fat in overweight or obese individuals with non-alcoholic fatty liver disease and hypertriglyceridemia. METHODS: Seventy-eight patients were randomized to receive oral doses of 4 g OM-3CA (n = 25), 200 mg fenofibrate (n = 27), or placebo (n = 26) for 12 weeks in a double-blind, parallel-group study...
August 10, 2018: Journal of Clinical Lipidology
Zahra Aryan, Negar Mahmoudi, Ali Sheidaei, Shahabeddin Rezaei, Zohreh Mahmoudi, Kimyia Gohari, Nazila Rezaei, Mohammad Javad Hajipour, Arezou Dilmaghani-Marand, Farideh Razi, Mahdi Sabooni, Farzad Kompani, Alireza Delavari, Bagher Larijani, Farshad Farzadfar
BACKGROUND: Hypercholesterolemia is one of the modifiable risk factors for atherosclerosis and cardiovascular diseases. Prevention and treatment of hypercholesterolemia and other lipid abnormalities require reliable data regarding the current prevalence of these abnormalities in the country. OBJECTIVE: This study aims to determine the current prevalence, awareness, and treatment of lipid abnormalities in Iran. METHODS: We planned to recruit 31,050 individuals who are 18 years old and above and take blood samples from individuals who are 25 years and above as representative sample at national and provincial levels in 2016...
August 10, 2018: Journal of Clinical Lipidology
Flore Duranton, Jonas Laget, Nathalie Gayrard, Jean-Sébastien Saulnier-Blache, Ulrika Lundin, Joost P Schanstra, Harald Mischak, Klaus M Weinberger, Marie-Françoise Servel, Angel Argilés
BACKGROUND: Various alterations in lipid metabolism have been observed in patients with chronic kidney disease (CKD). OBJECTIVES: To determine the levels of lipid species in plasma from CKD and hemodialysis (HD) patients and test their association with CKD severity and patient outcome. METHODS: Seventy-seven patients with CKD stage 2 to HD were grouped into classes of CKD severity at baseline and followed-up for 3.5 years for the occurrence of transition to HD or death (combined outcome)...
August 1, 2018: Journal of Clinical Lipidology
María José Ariza, José Rioja, Daiana Ibarretxe, Ana Camacho, José Luis Díaz-Díaz, Alipio Mangas, Julio A Carbayo-Herencia, Pablo Ruiz-Ocaña, Itziar Lamíquiz-Moneo, Daniel Mosquera, Pedro Sáenz, Luis Masana, Ovidio Muñiz-Grijalvo, Sofía Pérez-Calahorra, Pedro Valdivielso
BACKGROUND: Familial chylomicronemia syndrome (FCS) is an extremely rare lipoprotein disorder caused by mutations in at least 5 genes of the lipoprotein lipase (LPL) complex. OBJECTIVE: This work shows the molecular analysis of patients diagnosed with FCS, who attended the Spanish Arteriosclerosis Society lipid units and were included in the National Dyslipidemia Registry. METHODS: Among the 238 patients registered with severe hypertriglyceridemia (fasting triglycerides >1000 mg/dL), 26 were diagnosed with FCS as they had confirmed postheparin plasma LPL activity deficiency and/or homozygosity for loss-of-function mutations in LPL, GPIHBP1, APOC2, LMF1, or Apolipoprotein A5 (APOA5)...
August 1, 2018: Journal of Clinical Lipidology
Xavier Hermant, Charlotte Delay, Amandine Flaig, Jimena Luque-Bedregal, Gilbert Briand, Marie-Adélaïde Bout, Dominique Cottel, Aline Wagner, Dominique Arveiler, Chantal Simon, Jean Ferrières, Jean-Bernard Ruidavets, Brigitte Laillet, Philippe Amouyel, Jean Dallongeville, Aline Meirhaeghe, Julie Dumont
BACKGROUND: Blood polyunsaturated fatty acid (PUFA) levels are determined by diet and by endogenous synthesis via Δ5- and Δ6-desaturases (encoded by the FADS1 and FADS2 genes, respectively). Genome-wide association studies have reported associations between FADS1-FADS2 polymorphisms and the plasma concentrations of PUFAs, HDL- and LDL-cholesterol, and triglycerides. However, much remains unknown regarding the molecular mechanisms explaining how variants affect the function of FADS1-FADS2 genes...
July 31, 2018: Journal of Clinical Lipidology
Amy W Zawacki, Ann Dodge, Kaitlin M Woo, J Carter Ralphe, Amy L Peterson
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) level and lipoprotein(a) [Lp(a)] ≥ 50 mg/dL predict atherosclerotic cardiovascular disease (ASCVD) risk in adults with familial hypercholesterolemia (FH), but their role for children with FH is less clear. OBJECTIVE: This study examined the relationship between elevated Lp(a) and LDL-C levels in a pediatric population with FH and onset of ASCVD in family members. METHODS: Retrospective review of pediatric patients with FH identified LDL-C, Lp(a), and family history of ASCVD...
July 31, 2018: Journal of Clinical Lipidology
Mark M Mitsnefes, Jessica Fitzpatrick, Stephen M Sozio, Bernard G Jaar, Michelle M Estrella, Jose M Monroy-Trujillo, Wujuan Zhang, Kenneth Setchell, Rulan S Parekh
BACKGROUND: Recent population-based studies identified plasma sphingolipids as independent predictors of increased cardiovascular disease (CVD) morbidity and mortality. Understanding the impact of sphingolipids on CVD outcomes in patients on dialysis, who suffer from higher risk of these conditions, is important for risk assessment and treatment. OBJECTIVE: To measure plasma sphingolipid levels and determine their associations with CVD in adults initiating maintenance hemodialysis...
July 30, 2018: Journal of Clinical Lipidology
Miklós Péterfy, Candy Bedoya, Carola Giacobbe, Carmen Pagano, Marco Gentile, Paolo Rubba, Giuliana Fortunato, Maria Donata Di Taranto
BACKGROUND: Severe hypertriglyceridemia is a rare disease characterized by triglyceride levels higher than 1000 mg/dL (11.3 mmol/L) and acute pancreatitis. The disease is caused by pathogenic variants in genes encoding lipoprotein lipase (LPL), apolipoprotein A5, apolipoprotein C2, glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1, and lipase maturation factor 1 (LMF1). OBJECTIVE: We aim to identify the genetic cause of severe hypertriglyceridemia and characterize the new variants in a patient with severe hypertriglyceridemia...
July 25, 2018: Journal of Clinical Lipidology
Emilie Capel, Camille Vatier, Pascale Cervera, Tanya Stojkovic, Emmanuel Disse, Anne-Ségolène Cottereau, Martine Auclair, Marie-Christine Verpont, Héléna Mosbah, Pierre Gourdy, Sara Barraud, Anne Miquel, Stephan Züchner, Olivier Lascols, Corinne Vigouroux, Isabelle Jéru
BACKGROUND: Multiple symmetric lipomatosis (MSL) is characterized by upper-body lipomatous masses frequently associated with metabolic and neurological signs. MFN2 pathogenic variants were recently implicated in a very rare autosomal recessive form of MSL. MFN2 encodes mitofusin-2, a mitochondrial fusion protein previously involved in Charcot-Marie-Tooth neuropathy. OBJECTIVE: To investigate the clinical, metabolic, tissular, and molecular characteristics of MFN2-associated MSL...
July 25, 2018: Journal of Clinical Lipidology
Bruno Ramos-Molina, Daniel Castellano-Castillo, Juan Alcaide-Torres, Óscar Pastor, Resi de Luna Díaz, Jordi Salas-Salvadó, Javier López-Moreno, José C Fernández-García, Manuel Macías-González, Fernando Cardona, Francisco J Tinahones
BACKGROUND: Bariatric surgery (BS) is the most effective treatment for severe obesity. Our group and others have previously reported that the type of BS (restrictive vs malabsorptive) can lead to different effects on the lipid profile and glucose homeostasis in morbidly obese patients. Furthermore, BS exerts significant changes in lipid metabolism, which are not yet fully understood and that might be dependent of surgical technique. OBJECTIVE: The objective of this study was to evaluate the differential changes in the serum lipidomic profile of morbidly obese subjects who underwent two different BS techniques: sleeve gastrectomy (SG) (restrictive) and biliopancreatic diversion (BPD) (malabsorptive)...
July 25, 2018: Journal of Clinical Lipidology
Jeffrey L Probstfield, William E Boden, Todd Anderson, Kelley Branch, Moti Kashyap, Jerome L Fleg, Patrice Desvigne-Nickens, Ruth McBride, Mark McGovern
BACKGROUND: Epidemiologic studies have shown that low levels of high-density lipoprotein-cholesterol (HDL-C) and elevated triglycerides are independent predictors of cardiovascular (CV) events, though randomized trials of HDL-C-raising therapies to reduce clinical events have been largely disappointing. The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes (AIM-HIGH) trial failed to show that extended release niacin (ERN) reduced CV events in patients with atherogenic dyslipidemia who were on statin-based therapy...
July 25, 2018: Journal of Clinical Lipidology
Jenny Leung, Jessica Louise Brady, Martin Andrew Crook
This case report describes a patient who developed a mixed hyperlipidemia and severe hypertriglyceridemia (>20 mmol/L or 1772 mg/dL) while receiving capecitabine chemotherapy. After lipid-lowering treatment (statin and omega-3 acid ethyl esters) and completion of chemotherapy, her lipid levels had been significantly reduced. Other secondary causes of hyperlipidemia were also investigated. In view of the abnormal lipid results worsened by capecitabine, we suggest that careful lipid monitoring and thorough lipid management are important in such patients to avoid acute pancreatitis...
July 25, 2018: Journal of Clinical Lipidology
Elinor V Hanna, Sara Simonelli, Sarah Chamney, Alice Ossoli, Robert N Mullan
A 29-year-old lady was diagnosed with lecithin:cholesterol acyltransferase (LCAT) deficiency having presented with bilateral corneal clouding, severely reduced high density lipoproteins cholesterol, and proteinuria. She is a compound heterozygote with two LCAT gene mutations, one of which is novel, c.321C>A in exon 3. Surprisingly, the level of proteinuria significantly improved during pregnancy, despite stopping the angiotensin-converting enzyme inhibitor. However, LCAT concentration and activity remained identical during pregnancy and postpartum...
July 21, 2018: Journal of Clinical Lipidology
Byoungjin Park, Yong-Jae Lee
BACKGROUND: Metabolic syndrome (MetS) is clinically important because of its association with increased risk of sudden cardiac death, as well as cardiovascular disease-related mortality. Data between MetS and prolonged corrected QT (QTc) intervals, a useful predictor of sudden cardiac death, are limited in apparently healthy adults. OBJECTIVE: This study determined the association between MetS and QTc interval in apparently healthy Korean men and women. METHODS: We examined the association between MetS and QTc interval in 2157 Korean adults (1317 men and 840 women) in a health examination program but excluded participants with a history of ischemic heart disease, stroke, cardiac arrhythmia, cancer, thyroid, respiratory, renal, hepatobiliary, or rheumatologic disease...
July 20, 2018: Journal of Clinical Lipidology
Sotirios Tsimikas, Sergio Fazio, Nicholas J Viney, Shuting Xia, Joseph L Witztum, Santica M Marcovina
BACKGROUND: Lipoprotein(a) [Lp(a)] is reported as Lp(a) particle mass (mg/dL) or molar concentration of apolipoprotein(a) [apo(a)] (nmol/L), which is considered the gold standard. Values are often converted from one measurement to the other but the validity of this is unknown. OBJECTIVES: To quantify the relationship between Lp(a) molar concentration and Lp(a) mass in the context of various Lp(a) level thresholds and apo(a) isoform size. METHODS: In all samples, Lp(a) levels in molar concentration and apo(a) isoform size were determined at the Northwest Lipid Metabolism and Diabetes Research Laboratories (NLMDRL)...
July 20, 2018: Journal of Clinical Lipidology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"